Solid Biosciences Inc (SLDB) — 13F Filings Explorer (Q2 2026)

SLDB ranks #3568 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

SLDB is a top-conviction position for Monashee Investment Management LLC — at 8.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in SLDB belongs to Ra Capital Management, L.p., but the position matters far more to Monashee Investment Management LLC, who has 8.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ra Capital Management, L.p. has added to its SLDB position for two straight quarters, increasing it by $87.5M to reach $120.2M today.

Ikarian Capital, LLC has trimmed its SLDB position for two straight quarters, cutting it by $2.9M while still holding $429.1K.

SLDB is down 3.6% today, but institutions show net buying of $205.7M this quarter — a divergence between today's price move and the underlying institutional flow.

SLDB reported a net loss of $207.1M over the trailing twelve months.

• Not yet profitable — net loss of $207.1M over the trailing twelve months
• Net income declined year over year, from -$154.1M to -$207.1M
• Operating cash flow was negative, using $156.3M in cash
• Current ratio of 6.14x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.29x equity — within a conventional range